Literature DB >> 14576730

Comparative analysis of T-cell receptor gene rearrangements at diagnosis and relapse of T-cell acute lymphoblastic leukemia (T-ALL) shows high stability of clonal markers for monitoring of minimal residual disease and reveals the occurrence of second T-ALL.

T Szczepański1, V H J van der Velden, T Raff, D C H Jacobs, E R van Wering, M Brüggemann, M Kneba, J J M van Dongen.   

Abstract

A total of 28 children and nine adults with relapsed T-ALL were analyzed for the configuration of their T-cell receptor (TCR) and TAL1 genes at diagnosis and relapse to evaluate their stability throughout the disease course. A total of 150 clonal TCR and TAL1 gene rearrangements were identified in the 37 patients at diagnosis. In 65% of cases all rearrangements and in 27% of cases most rearrangements found at diagnosis were preserved at relapse. Two children with unusually late T-ALL recurrences displayed completely different TCR gene rearrangement sequences between diagnosis and relapse. This indicates that a proportion of very late T-ALL recurrences might represent second T-ALL. Specifically, 88% of clonal rearrangements identified at diagnosis in truly relapsed T-ALL were preserved at relapse. This is significantly higher as compared to previously studied precursor-B-ALL ( approximately 70%). Thus, from biological point of view, immunogenotype of T-ALL is more stable as compared with precursor-B-ALL. The overall stability of TCR gene rearrangements was higher in adult T-ALL (97%) than in childhood T-ALL (86%). Based on the stability of TCR gene rearrangements, we propose a strategy for PCR target selection (TCRD+TAL1 --> TCRB --> TCRG), which probably allows reliable minimal residual disease detection in all T-ALL patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14576730     DOI: 10.1038/sj.leu.2403081

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  16 in total

1.  Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01.

Authors:  Jianbiao Zhou; Meredith A Goldwasser; Aihong Li; Suzanne E Dahlberg; Donna Neuberg; Hongjun Wang; Virginia Dalton; Kathryn D McBride; Stephen E Sallan; Lewis B Silverman; John G Gribben
Journal:  Blood       Date:  2007-05-07       Impact factor: 22.113

2.  CD56 expression in T-cell acute lymphoblastic leukemia is associated with non-thymic phenotype and resistance to induction therapy but no inferior survival after risk-adapted therapy.

Authors:  Lars Fischer; Nicola Gökbuget; Stefan Schwartz; Thomas Burmeister; Harald Rieder; Monika Brüggemann; Dieter Hoelzer; Eckhard Thiel
Journal:  Haematologica       Date:  2008-12-23       Impact factor: 9.941

Review 3.  Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies.

Authors:  Jacques J M van Dongen; Vincent H J van der Velden; Monika Brüggemann; Alberto Orfao
Journal:  Blood       Date:  2015-05-21       Impact factor: 22.113

4.  A biomimetic five-module chimeric antigen receptor (5MCAR) designed to target and eliminate antigen-specific T cells.

Authors:  Shio Kobayashi; Martin A Thelin; Heather L Parrish; Neha R Deshpande; Mark S Lee; Alborz Karimzadeh; Monika A Niewczas; Thomas Serwold; Michael S Kuhns
Journal:  Proc Natl Acad Sci U S A       Date:  2020-11-02       Impact factor: 11.205

5.  Conditional Sure Independence Screening.

Authors:  Emre Barut; Jianqing Fan; Anneleen Verhasselt
Journal:  J Am Stat Assoc       Date:  2016-10-18       Impact factor: 5.033

6.  Prognosis of children with mixed phenotype acute leukemia treated on the basis of consistent immunophenotypic criteria.

Authors:  Ester Mejstrikova; Jana Volejnikova; Eva Fronkova; Katerina Zdrahalova; Tomas Kalina; Jaroslav Sterba; Yahia Jabali; Vladimir Mihal; Bohumir Blazek; Zdena Cerna; Daniela Prochazkova; Jiri Hak; Zuzana Zemanova; Marie Jarosova; Alexandra Oltova; Petr Sedlacek; Jiri Schwarz; Jan Zuna; Jan Trka; Jan Stary; Ondrej Hrusak
Journal:  Haematologica       Date:  2010-02-09       Impact factor: 9.941

7.  Evolution of Tumor Clones in Adult Acute Lymphoblastic Leukemia.

Authors:  S Yu Smirnova; Yu V Sidorova; N V Ryzhikova; K A Sychevskaya; E N Parovichnikova; A B Sudarikov
Journal:  Acta Naturae       Date:  2016 Oct-Dec       Impact factor: 1.845

Review 8.  Is Next-Generation Sequencing the way to go for Residual Disease Monitoring in Acute Lymphoblastic Leukemia?

Authors:  Michaela Kotrova; Jan Trka; Michael Kneba; Monika Brüggemann
Journal:  Mol Diagn Ther       Date:  2017-10       Impact factor: 4.074

9.  Prognostic implications of NOTCH1 and FBXW7 mutations in adults with T-cell acute lymphoblastic leukemia treated on the MRC UKALLXII/ECOG E2993 protocol.

Authors:  Marc R Mansour; Maria L Sulis; Veronique Duke; Letizia Foroni; Sarah Jenkinson; Kenneth Koo; Christopher G Allen; Rosemary E Gale; Georgina Buck; Sue Richards; Elisabeth Paietta; Jacob M Rowe; Martin S Tallman; Anthony H Goldstone; Adolfo A Ferrando; David C Linch
Journal:  J Clin Oncol       Date:  2009-07-27       Impact factor: 44.544

Review 10.  Immune Gene Rearrangements: Unique Signatures for Tracing Physiological Lymphocytes and Leukemic Cells.

Authors:  Michaela Kotrova; Nikos Darzentas; Christiane Pott; Claudia D Baldus; Monika Brüggemann
Journal:  Genes (Basel)       Date:  2021-06-27       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.